Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A50668 | 35308224 | Front Pharmacol | Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50672 | 35307033 | BMC Med | Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). | 2022 | Details |
| A50680 | 35304846 | Lancet HIV | Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. | 2022 | Details |
| A50686 | 35302256 | Aliment Pharmacol Ther | Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). | 2022 | Details |
| A50688 | 35302179 | Intern Emerg Med | Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease. | 2022 | Details |
| A50699 | 35295895 | Visc Med | Metabolic Surgery: Paradigm Shift in Metabolic Syndrome/Diabetes Therapy. | 2022 | Details |
| A50703 | 35294499 | PLoS One | Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model. | 2022 | Details |
| A50708 | 35292355 | Prostaglandins Other Lipid Mediat | The role of Resolvin D1 in liver diseases. | 2022 | Details |
| A50712 | 35290569 | Radiol Med | Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD. | 2022 | Details |
| A50718 | 35288342 | Clin Gastroenterol Hepatol | Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications. | 2022 | Details |
| A50719 | 35288065 | Dig Liver Dis | Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity. | 2022 | Details |
| A50721 | 35287643 | BMC Endocr Disord | Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. | 2022 | Details |
| A50723 | 35286803 | J Proteome Res | Serum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. | 2022 | Details |
| A50726 | 35285996 | J Magn Reson Imaging | Prospective Evaluation of Virtual MR Elastography With Diffusion-Weighted Imaging in Subjects With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50727 | 35285832 | J Vis Exp | 3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A50728 | 35285529 | Aliment Pharmacol Ther | Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. | 2022 | Details |
| A50731 | 35284290 | Quant Imaging Med Surg | Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores. | 2022 | Details |
| A50732 | 35284276 | Quant Imaging Med Surg | Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A50734 | 35283365 | J Obes Metab Syndr | Hepatic Fibrosis and Steatosis in Metabolic Syndrome. | 2022 | Details |
| A50736 | 35283265 | Diabetes Res Clin Pract | Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. | 2022 | Details |
| A50741 | 35282455 | Front Endocrinol (Lausanne) | Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2022 | Details |
| A50743 | 35280896 | Front Med (Lausanne) | Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A50746 | 35280674 | Int J Biol Sci | Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway. | 2022 | Details |
| A50747 | 35279807 | Indian J Gastroenterol | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. | 2022 | Details |
| A50752 | 35277756 | Eur J Nutr | Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients. | 2022 | Details |
| A50753 | 35277075 | Nutrients | Simvastatin Improves Microcirculatory Function in Nonalcoholic Fatty Liver Disease and Downregulates Oxidative and ALE-RAGE Stress. | 2022 | Details |
| A50754 | 35277054 | Nutrients | Beneficial Activities of Alisma orientale Extract in a Western Diet-Induced Murine Non-Alcoholic Steatohepatitis and Related Fibrosis Model via Regulation of the Hepatic Adiponectin and Farnesoid X Receptor Pathways. | 2022 | Details |
| A50762 | 35276383 | Comp Biochem Physiol B Biochem Mol Biol | Aggravation of hepatic lipidosis in red-footed tortoise Chelonoidis carbonaria with age is associated with alterations in liver mitochondria. | 2022 | Details |
| A50767 | 35274325 | Aliment Pharmacol Ther | Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. | 2022 | Details |
| A50772 | 35271950 | J Hepatol | Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. | 2022 | Details |
| A50775 | 35269955 | Int J Mol Sci | Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50776 | 35269912 | Int J Mol Sci | Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. | 2022 | Details |
| A50778 | 35269812 | Int J Mol Sci | Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50779 | 35269779 | Int J Mol Sci | Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. | 2022 | Details |
| A50780 | 35269515 | Cells | Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery. | 2022 | Details |
| A50781 | 35269495 | Cells | Cell-Type Resolved Insights into the Cis-Regulatory Genome of NAFLD. | 2022 | Details |
| A50782 | 35268536 | J Clin Med | Hyperuricemia Is Associated with Significant Liver Fibrosis in Subjects with Nonalcoholic Fatty Liver Disease, but Not in Subjects without It. | 2022 | Details |
| A50784 | 35268293 | J Clin Med | The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study. | 2022 | Details |
| A50788 | 35266164 | Aliment Pharmacol Ther | Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. | 2022 | Details |
| A50790 | 35265372 | J Nutr Metab | The Predictive Role of Parathyroid Hormone for Nonalcoholic Fatty Liver Disease following Bariatric Surgery. | 2022 | Details |
| A50791 | 35265044 | Front Endocrinol (Lausanne) | Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction. | 2022 | Details |
| A50800 | 35261068 | Fundam Clin Pharmacol | Inhibition of plasminogen suppresses fibrosis and macrophage foaming in a nonalcoholic steatohepatitis mouse model. | 2022 | Details |
| A50809 | 35222274 | Front Endocrinol (Lausanne) | J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes. | 2022 | Details |
| A50820 | 35164434 | Clin Mol Hepatol | Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs. | 2022 | Details |
| A50821 | 35151862 | Clin Gastroenterol Hepatol | Reply to: Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. | 2022 | Details |
| A50822 | 35143946 | Gene | Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study. | 2022 | Details |
| A50829 | 35122404 | Hepatol Commun | Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. | 2022 | Details |
| A50830 | 35121749 | Sci Rep | A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. | 2022 | Details |
| A50831 | 35119217 | J Diabetes Investig | Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now. | 2022 | Details |
| A50834 | 35092319 | Hepatology | Letter to the editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis? | 2022 | Details |
| A50854 | 34950862 | JHEP Rep | Strategies for a two-step liver fibrosis assessment in clinical practice. | 2021 | Details |
| A50870 | 34728983 | J Clin Exp Hepatol | Predictors of in-hospital Outcomes in Patients With Cirrhosis and Coronavirus Disease-2019. | 2021 | Details |
| A50883 | 34521766 | Gut | Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? | 2021 | Details |
| A50887 | 34402474 | Eur J Gastroenterol Hepatol | Long-standing effect of cholecystectomy in patients with metabolic-associated fatty liver disease. | 2021 | Details |
| A50892 | 34224877 | Clin Gastroenterol Hepatol | Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. | 2021 | Details |
| A50900 | 35783905 | Hepatol Forum | The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. | 2021 | Details |
| A50910 | 33733940 | Nutr Cancer | Predictors of Sarcopenia in an Obese Asian Population. | 2021 | Details |
| A50912 | 33731597 | Eur J Gastroenterol Hepatol | Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol/saturated fatty acids. | 2021 | Details |
| A50913 | 33675319 | Transplantation | Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation. | 2022 | Details |
| A50917 | 33549867 | Clin Gastroenterol Hepatol | Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States. | 2021 | Details |
| A50923 | 33299844 | Hepatobiliary Surg Nutr | Automated quantification of fibrosis-related parameters using dual-photon microscopy replace diagnosis of pathologists in NAFLD. | 2020 | Details |
| A50940 | 32039363 | JHEP Rep | The current issue of JHEP Reports. | 2019 | Details |
| A50941 | 31954067 | Hepatology | PNPLA3 Genotype and Risk of Liver and All-Cause Mortality. | 2020 | Details |
| A50987 | 28176361 | Hepatology | The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. | 2017 | Details |
| A50995 | 27511135 | Aliment Pharmacol Ther | Editorial: non-invasive assessment of hepatic fibrosis in alpha-1 antitrypsin deficiency using magnetic resonance elastography - authors' reply. | 2016 | Details |
| A51029 | 23519833 | Hepatology | From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. | 2013 | Details |
| A51031 | 23376892 | J Hepatol | Regular coffee: a magic bullet or a naked gun? Regular coffee but not espresso drinking is protective against fibrosis in NAFLD. | 2013 | Details |
| A51032 | 23376891 | J Hepatol | Reply to: "regular coffee: a magic bullet or a naked gun? Regular coffee but not espresso drinking is protective against fibrosis in NAFLD". | 2013 | Details |
| A51042 | 22087194 | Hepat Mon | Indirect markers of fibrosis in chronic liver diseases: Is aspartate transaminase-to-platelet ratio (APRI) a useful test? | 2011 | Details |
| A51043 | 22087165 | Hepat Mon | Commentary on: Aspartate transaminase to platelet ratio index (APRI): A simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases. | 2011 | Details |
| A51058 | 19349131 | Gastroenterol Clin Biol | [Noninvasive tools for the diagnosis of steatosis and fibrosis in patients with NAFLD]. | 2009 | Details |
| A51089 | 35803839 | J Diabetes Complications | Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. | 2022 | Details |
| A51103 | 35762039 | J Cell Physiol | Transforming growth factor-beta 1: A new factor reducing hepatic SHBG production in liver fibrosis. | 2022 | Details |
| A51104 | 35746590 | Viruses | Circulating MicroRNAs as a Tool for Diagnosis of Liver Disease Progression in People Living with HIV-1. | 2022 | Details |
| A51108 | 35727501 | Hepatol Int | Associations between intake of starchy and non-starchy vegetables and risk of hepatic steatosis and fibrosis. | 2022 | Details |
| A51118 | 35668318 | Hormones (Athens) | Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. | 2022 | Details |
| A51122 | 35658240 | Biomed Pharmacother | Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway. | 2022 | Details |
| A51123 | 35636492 | J Lipid Res | Membrane-bound O-acyltransferase 7 (MBOAT7)-driven phosphatidylinositol remodeling in advanced liver disease. | 2022 | Details |
| A51126 | 35614007 | Dig Liver Dis | Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. | 2022 | Details |
| A51131 | 35591814 | Hepatol Res | Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. | 2022 | Details |
| A51135 | 35533993 | Clin Gastroenterol Hepatol | The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. | 2022 | Details |
| A51136 | 35528980 | J Clin Transl Hepatol | Vibration-controlled Transient Elastography for Assessment of Liver Fibrosis at a USA Academic Medical Center. | 2021 | Details |
| A51139 | 35516840 | J Toxicol Pathol | CD44 expression in the bile duct epithelium is related to hepatic fibrosis in nonalcoholic steatohepatitis rats induced by a choline-deficient, methionine-lowered, L-amino acid diet. | 2021 | Details |
| A51141 | 35511608 | Clin Infect Dis | HIV is associated with elevated FibroScan-AST (FAST) score. | 2022 | Details |
| A51143 | 35504562 | Clin Gastroenterol Hepatol | Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy. | 2022 | Details |
| A51145 | 35491473 | Alcohol Clin Exp Res | Chronic ethanol consumption plus an atherogenic diet cause metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout mice. | 2022 | Details |
| A51180 | 35337981 | Clin Gastroenterol Hepatol | The Natural History of Advanced Chronic Liver Disease Defined by Transient Elastography. | 2022 | Details |
| A51226 | 10691383 | Hepatology | Iron and fibrosis in nonalcoholic fatty liver disease. | 2000 | Details |
| A51228 | 10498632 | Hepatology | Hepatic iron and nonalcoholic fatty liver disease. | 1999 | Details |
| A51231 | 1621236 | Ther Umsch | [Liver biopsy in suspected alcoholic liver damage]. | 1992 | Details |
| A51233 | 3200124 | Liver | Hypoceruloplasminemia and ultrastructural changes resembling Wilson's disease in nonalcoholic liver steatosis. A clinical and pathological study of five cases. | 1988 | Details |
| A51235 | 3343931 | Metabolism | Independent effects of liver disease and chronic alcoholism on thyroid function and size: the possibility of a toxic effect of alcohol on the thyroid gland. | 1988 | Details |
| A51243 | 857661 | Am J Dig Dis | Possible relationship between the rate of ethanol metabolism and the severity of hepatic damage in chronic alcoholics. | 1977 | Details |
| A51283 | 468098 | Hokkaido Igaku Zasshi | [Chronic hepatitis--clinicopathological studies of 687 cases (author's transl)]. | 1979 | Details |
| A51287 | 409197 | AJR Am J Roentgenol | Hepatic venography and wedge hepatic vein pressure measurements in diffuse liver disease. | 1977 | Details |
| A51296 | 35812273 | Kidney Int Rep | ACLY and CKD: A Mendelian Randomization Analysis. | 2022 | Details |
| A51300 | 35801591 | JCI Insight | Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. | 2022 | Details |
| A51301 | 35797110 | J Med Chem | Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A51303 | 35777586 | J Hepatol | Augmenter of liver regeneration: mitochondrial function and steatohepatitis. | 2022 | Details |